Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915727 · ClinicalTrials.gov registry record · Phase 3
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
A Phase 3 study of Malignant Pelvic Neoplasm and Childhood Malignant Solid Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06915727 is a Phase 3 study of Malignant Pelvic Neoplasm and Childhood Malignant Solid Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06915727, a Phase 3 study of Malignant Pelvic Neoplasm and Childhood Malignant Solid Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Pafolacianine is a fluorescent imaging agent that targets folate receptors which are overexpressed in many cancers and is used with near infrared (NIR) imaging during surgery to identify tumor cells. NIR uses a special camera that uses wavelengths in the infrared range to visualize and locate the tumor cells that are lit up by the pafolacianine. Giving pafolacianine for NIR imaging may work better than other imaging agents in identifying cancerous lesions in pediatric patients with solid tumors.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Surgical Procedure
- PROCEDURE Near Infrared Imaging
- DRUG Pafolacianine Sodium
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06915727
The ClinicalTrials.gov registry entry for NCT06915727 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Malignant Pelvic Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT06915727 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06915727 about?
NCT06915727 is a clinical study titled "An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors". This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Pafolacianine is a fluores...
What is the current status of trial NCT06915727?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2025-04-15. Estimated completion is 2027-05-01.
What conditions does trial NCT06915727 study?
This clinical trial studies the following conditions: Malignant Pelvic Neoplasm, Childhood Malignant Solid Neoplasm, Malignant Abdominal Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Neck Neoplasm.
What interventions are being tested in trial NCT06915727?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Surgical Procedure (PROCEDURE), Near Infrared Imaging (PROCEDURE), Pafolacianine Sodium (DRUG).
Who is sponsoring clinical trial NCT06915727?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915727 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Pelvic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Malignant Pelvic Neoplasm
All registered trials for this condition
Childhood Malignant Solid Neoplasm
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.